A Randomized Phase II Study of Adjuvant Concurrent Radiation and Chemotherapy versus Radiation and Chemotherapy versus Radiation Alone in Resected High-Risk Malignant Salivary Gland Tumors

ID Number 09-0762 (2)

Principal Investigator(s)
Richard Bakst

Department(s) or Division(s)
Radiation Oncology


The standard treatment for cancer of the salivary gland is surgery, and all patients will have had surgery before taking part in this study. Although the surgery may have removed your cancer, features of your disease suggest that you are at an increased risk for your cancer to return.

In patients at risk for disease recurrence after surgery, radiation therapy to the head and neck is frequently recommended after surgery. The purpose of this study is to test whether the use of chemotherapy with radiation will improve the results after surgery and radiation alone. Post-operative radiation represents a standard treatment for this disease. The use of chemotherapy is approved by the FDA for this indication.

The study will compare the effects, good and/or bad, of radiation and chemotherapy with radiation alone on you and your salivary gland cancer to find out which is better at reducing the chance that your cancer will come back.

You may qualify to take part in this research study because you have malignant salivary gland tumor and you underwent a resection surgery.

Contact Information
Monika Anand
(212) 824-7501

Recruiting Patients: No